# Dendritic Cell Vaccine in Treating Patients With Indolent B-Cell Lymphoma or Multiple Myeloma

> **NCT00937183** · NA · COMPLETED · sponsor: **Jan Walewski** · enrollment: 12 (actual)

## Conditions studied

- Lymphoma
- Multiple Myeloma and Plasma Cell Neoplasm

## Interventions

- **BIOLOGICAL:** autologous lymphoma cell lysate-pulsed autologous dendritic cell vaccine
- **BIOLOGICAL:** autologous lymphoma cell/allogeneic dendritic cell electrofusion hybrid vaccine
- **BIOLOGICAL:** autologous lymphoma cell/autologous dendritic cell electrofusion hybrid vaccine

## Key facts

- **NCT ID:** NCT00937183
- **Lead sponsor:** Jan Walewski
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-09
- **Primary completion:** 2017-06
- **Final completion:** 2017-12
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2019-08-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00937183

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00937183, "Dendritic Cell Vaccine in Treating Patients With Indolent B-Cell Lymphoma or Multiple Myeloma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00937183. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*